Anixa Biosciences (a company engaged in the prevention and treatment of infectious diseases), has announced on Monday that it has collaborated with the OntoChem GmbH for the research and development of Anti-Viral Covid-19 Drug.
Boss of Anixa Biosciences, Dr. Amit Kumar, said, “We are pleased to be working with OntoChem for the discovery and development of new drug candidates for COVID-19. OntoChem has developed the world’s largest chemistry and gene ontology databases and search capability and has assembled large, proprietary, in silico libraries of chemical compounds that could disrupt the ability of SARS-CoV-2 to replicate.”
“In silico refers to the existence of compounds in a computer database with detailed molecular structures. In addition to its proprietary libraries, OntoChem has access to other libraries of potential drug compounds. After recent publications of the RNA sequence, as well as key crystal structures of certain enzymes of the virus, we approached OntoChem to collaborate on a project to utilize their proprietary technologies for drug discovery,” Dr. Kumar further said.
On the other hand, the Anixa Biosciences has got years of experience in research and development of infectious diseases, including SARS-virus, which emerged in 2003.
The CEO and President of OntoChem, Dr. Lutz Weber, said, “The discovery of investigational drug candidates can ordinarily take several years. However, through this collaboration, we anticipate identifying multiple drug candidates in as little as six months’ time. To do this, we will utilize advanced computational methods, machine learning and molecular modeling techniques to perform in silico screening of over 1.2 billion compounds to evaluate if any could disrupt one of two key enzymes of the virus.”
“This comprehensive group of over 1.2 billion compounds includes publicly available and OntoChem’s proprietary libraries. To our knowledge, this project will utilize the largest number of compounds with the broadest chemical diversity ever tried against SARS-CoV-2. Due to the size and diversity of the compounds, we are very optimistic about success. After identifying key compounds, we will have them synthesized and evaluated in biological and cellular assays to assess their potency. Following that work, we hope to have a small number of candidates that can be taken into animal studies,” Dr. Weber further said.
Alonzo Coleman is our freelance contributor. He is responsible for covering developments in Health and Tech categories. Alonzo writes related to the Health Category. He manages to cover anything thrown at him in these two verticals owing to his natural inclination towards Health.
Email: [email protected]
Address: 4686 Mudlick Road, WALKER, Kentucky 40997, USA
Contact number: 509-546-5081